Technical Data
M2867-61B
MARCH-VII (Axotrophin, MARCH7, membrane-associated ring finger (C3HC4) 7, AXO, AXOT, DKFZP586F1122, MARCH-VII, RNF177)
Description:
Applications:
Suitable for use in ELISA. Other applications not tested.

Recommended Dilution:
Peptide ELISA: 1:4,000.
Western Blot: Preliminary experiments gave an approx 125kD band in Human Spleen and Tonsil lysates after 1ug/ml antibody staining. Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Peptide Blocking:
Corresponding peptide is available for Peptide Blocking studies. See M2867-61B-P. Antibody is typically 0.5mg/ml and peptide is supplied as a 100ul pellet. When peptide is reconstituted in 200ul water, the concentration would also be 0.5mg/ml. To start, the best ratio would be 1:1 (molar excess of peptide relative to antibody when identical volumes are mixed). Mix equal volumes of peptide and antibody at the required dilution and leave at ambient temperature. It is best is to have two identical blots to be incubated with equal amount of antibody, but one with the antibody pre-adsorbed to the peptide for 20min. Then incubate and develop the two blots in parallel.
TypeIsotypeCloneGrade
PabAffinity Purified
SizeStorageShippingSourceHost
100ug-20°CBlue IceHumanGoat
Concentration:
~0.5mg/ml
Immunogen:
A synthetic peptide from the C-terminus of aa--NFNQESEGRNT
Purity:
Purified by affinity chromatography.
Form
Supplied as a liquid in Tris saline, pH 7.2, 0.5% BSA, 0.02% sodium azide.
Specificity:
Recognizes human MARCH-VII. Species Crossreactivity: mouse, rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Evidence for functional inter-relationships between FOXP3, leukaemia inhibitory factor, and axotrophin/MARCH-7 in transplantation tolerance., Muthukumarana PA, Lyons GE, Miura Y, Thompson LH, Watson T, Green CJ, Shurey S, Hess AD, Rosengard BR, Metcalfe SM., Int Immunopharmacol. 2006 Dec 20;6(13-14):1993-2001. Epub 2006 Oct 17.